TY - JOUR
T1 - Fluoxetine and fractures after stroke
T2 - An individual patient data meta-analysis of three large randomized controlled trials of fluoxetine for stroke recovery
AU - Mead, Gillian
AU - Graham, Catriona
AU - Lundström, Erik
AU - Hankey, Graeme J.
AU - Hackett, Maree L.
AU - Billot, Laurent
AU - Näsman, Per
AU - Forbes, John
AU - Dennis, Martin
N1 - Publisher Copyright:
© 2025 World Stroke Organization.
PY - 2025/6
Y1 - 2025/6
N2 - Background: Observational studies have shown that selective serotonin reuptake inhibitors are associated with an increased risk of bone fractures, but the association can be confounded by indication and other sources of systematic bias that can be minimized in randomized controlled trials (RCTs). Aim: Our aim was to report the rate, site, context, and predictors of fractures after stroke, and whether the fractures modified the effect of fluoxetine on modified Rankin scale (mRS) at 6 months in an individual patient data meta-analysis of 5907 patients enrolled in three RCTs of fluoxetine (20 mg for 6 months) for stroke recovery. Methods: We classified fractures by treatment allocation, site (and thus likelihood of osteoporosis), and context, then performed multivariable analyses to explore the independent predictors of fractures. We explored whether the trend toward a poorer mRS at 6 months was explained by a fracture excess. Risk of bias was assessed using GRADE. Results: Among 5907 patients randomized at a mean of 6.6 days (SD 3.6) post-stroke onset and followed for 6 months, the number of fractures at 6 months was 93 (3.15%) in the fluoxetine group versus 41 (1.39%) in the control group (difference 1.76, 95% CI 0.10–2.51). However, 128 patients with fractures were suitable for further analyses. Of these, 102 (80%) were in sites typically affected by osteoporosis; 115 (90%) were associated with falls and 1 (1%) with a seizure. Independent fracture risk factors were female sex (hazard ratio (HR) 1.96; 95% CI 1.37–2.81, p = 0.0002), age > 70 years (HR 2.30, 95% CI 1.52–3.49, p < 0.001), previous fractures (HR 0.63 for no previous fractures, 95% CI 0.42–0.94, p = 0.0227), and randomized treatment (fluoxetine) (HR 2.39; 95% CI 1.64–3.49, p < 0.001). The common odds ratio for the effect of fluoxetine on mRS at 6 months was unchanged after excluding fracture patients. Risk of bias was high for imprecision. Conclusion: Fractures were more common in the fluoxetine group but the absolute risk of fractures was small and risk estimates were imprecise. Most fractures occurred with a fall, and in osteoporotic locations. Fractures did not modify the effect of fluoxetine on functional outcome.
AB - Background: Observational studies have shown that selective serotonin reuptake inhibitors are associated with an increased risk of bone fractures, but the association can be confounded by indication and other sources of systematic bias that can be minimized in randomized controlled trials (RCTs). Aim: Our aim was to report the rate, site, context, and predictors of fractures after stroke, and whether the fractures modified the effect of fluoxetine on modified Rankin scale (mRS) at 6 months in an individual patient data meta-analysis of 5907 patients enrolled in three RCTs of fluoxetine (20 mg for 6 months) for stroke recovery. Methods: We classified fractures by treatment allocation, site (and thus likelihood of osteoporosis), and context, then performed multivariable analyses to explore the independent predictors of fractures. We explored whether the trend toward a poorer mRS at 6 months was explained by a fracture excess. Risk of bias was assessed using GRADE. Results: Among 5907 patients randomized at a mean of 6.6 days (SD 3.6) post-stroke onset and followed for 6 months, the number of fractures at 6 months was 93 (3.15%) in the fluoxetine group versus 41 (1.39%) in the control group (difference 1.76, 95% CI 0.10–2.51). However, 128 patients with fractures were suitable for further analyses. Of these, 102 (80%) were in sites typically affected by osteoporosis; 115 (90%) were associated with falls and 1 (1%) with a seizure. Independent fracture risk factors were female sex (hazard ratio (HR) 1.96; 95% CI 1.37–2.81, p = 0.0002), age > 70 years (HR 2.30, 95% CI 1.52–3.49, p < 0.001), previous fractures (HR 0.63 for no previous fractures, 95% CI 0.42–0.94, p = 0.0227), and randomized treatment (fluoxetine) (HR 2.39; 95% CI 1.64–3.49, p < 0.001). The common odds ratio for the effect of fluoxetine on mRS at 6 months was unchanged after excluding fracture patients. Risk of bias was high for imprecision. Conclusion: Fractures were more common in the fluoxetine group but the absolute risk of fractures was small and risk estimates were imprecise. Most fractures occurred with a fall, and in osteoporotic locations. Fractures did not modify the effect of fluoxetine on functional outcome.
KW - bone fractures
KW - falls
KW - fluoxetine
KW - Stroke
UR - https://www.scopus.com/pages/publications/105000205325
U2 - 10.1177/17474930251316164
DO - 10.1177/17474930251316164
M3 - Article
C2 - 39829374
AN - SCOPUS:105000205325
SN - 1747-4930
VL - 20
SP - 540
EP - 549
JO - International Journal of Stroke
JF - International Journal of Stroke
IS - 5
ER -